Drug intelligence / Profile preview

AMG 127

Development stage: Phase 1
Lead developer: Amgen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

AMG 127 is a monoclonal antibody developed by Amgen that acts as an antagonist of the Gastric Inhibitory Polypeptide Receptor (GIPR). It was primarily investigated for the treatment of metabolic disorders, including type 2 diabetes mellitus and potentially obesity. The drug's mechanism involves blocking GIPR signaling, which is part of a therapeutic strategy to improve metabolic health and glycemic control. While it reached Phase 1 clinical testing (NCT05141591), it was subsequently removed from Amgen's active development pipeline in 2023, with the company focusing on other metabolic candidates like the GIPR antagonist/GLP-1 agonist maridebart cafraglutide (AMG 133).

Targets

GIPR (Gastric inhibitory polypeptide receptor)

Beyond the preview

Go deeper on AMG 127.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMG 127.

Explore the full profile